Nuvation Bio Inc - Ordinary Shares - Class A
NUVB
Market Cap$668.35M
Close$
$0.30
84.7% downside
Current Fair Value
84.7% downsideOvervalued by 84.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $668.35 Million |
|---|---|
| Enterprise Value | $642.32 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.11 |
| Beta | 1.37 |
| Outstanding Shares | 338,612,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.1 |
|---|---|
| PEG | -0.42 |
| Price to Sales | - |
| Price to Book Ratio | 1.93 |
| Enterprise Value to Revenue | 58.62 |
| Enterprise Value to EBIT | -3.18 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Nuvation Bio Inc
36 employeesNuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically ...